Study shows use of EpiSwitch blood test can aid in treatment decision for rheumatoid arthritis

A study using Oxford BioDynamics’ EpiSwitch showed the blood test that looks for epigenetic biomarkers can help identify an inadequate response to using methotrexate (MTX) in treating early rheumatoid arthritis.

The study, which was recently published in the Journal of Translational Medicine, looked into whether the differences in genomic architecture represented by a chromosome conformation signature (CCS) in blood taken from people with early rheumatoid arthritis before they were administered methotrexate to see what the likelihood was that they would respond to such first-line disease-modifying antirheumatic drugs (DMARDs).

MTX is a primary treatment for new-onset rheumatoid arthritis; however, many patients do not respond to the therapy that can take at least six months for an indication of its effectiveness. In the meantime, substantial damage due to inflammation can occur during that timeframe, resulting in future disability and loss of function.

Results of the study “successfully showed that a CCS found in the blood samples” using the EpiSwitch was able to identify “with a high degree of accuracy” patients who wouldn’t respond well to MTX.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Oxford BioDynamics

    More articles like this

    Oxford BioDynamics

    EpiSwitch technology in Alzheimer’s disease

    Alzheimer’s disease (AD) is the most common form of dementia, and it accounts for an estimated 60% – 80% of cases. The hallmark pathologies of AD are the progressive accumulation of the protein fragment beta-amyloid (plaques)

    Oxford BioDynamics

    How are EpiSwitch markers detected?

    Introduction: Getting the basics right Oxford BioDynamics’ (OBD) EpiSwitch™ biomarker discovery platform combined with their newly enhanced detection technology gives the company valuable quantitative insights into chromosome conformations(DNA protein complexes) that regulate normal and disease biology

    Oxford BioDynamics

    Holos Life Sciences using EpiSwitch

    Epigenetics represents the impact of the combination of genetic, lifestyle and environmental factors on humans. We utilise EpiSwitch™, a proprietary biomarker discovery platform licensed from our AIM listed shareholder Oxford Biodynamics Plc. Based on the latest advances in gene

    Oxford BioDynamics

    Episwitch Methodology

    Oxford BioDynamics’ EpiSwitchTM platform is the first industrial platform for the discovery, evaluation, validation and monitoring of a novel class of epigenetic biomarkers known as ‘chromosome conformation signatures’ (“CCSs”). CCSs provide a robust, stable framework of

    Oxford BioDynamics

    5 Ways to Help Kids Cope with a Parent’s ALS

    One of my biggest concerns is how my husband’s ALS will affect our children. They were both under 5 when Todd was diagnosed and while they are growing up, their father continues to lose strength. A

    Oxford BioDynamics

    EpiSwitch Technology

    EpiSwitch™ is a proprietary industrial platform for the discovery, evaluation, validation and monitoring of a novel class of epigenetic biomarkers known as ‘chromosome conformation signatures’ (“CCSs”).  CCSs can provide a compelling, stable framework from which changes in the regulation of

    Oxford BioDynamics

    Rare Disease Day 2020

    An abundance of events are afoot around the world to mark Rare Disease Day 2020 on Feb. 29. The activities are focused on heightening awareness about rare diseases and the hundreds of millions of individuals they are thought

    Oxford BioDynamics

    Oxford BioDynamics’ EpiSwitchFeatured in Presentations

    Data yielded by application of OBD’s 3D genome architecture technology platform, EpiSwitch™ was presented at The Society for Immunotherapy of Cancer’s 34th Annual Meeting. The poster presentations indicate that the biomarkers identified by EpiSwitch, using blood samples

    Oxford BioDynamics

    Dementia rates in Europe to double by 2050

    Today, at a European Parliament lunch debate hosted by Christophe Hansen MEP (Luxembourg), Alzheimer Europe launched a new report presenting the findings of its collaborative analysis of recent prevalence studies and setting out updated prevalence rates

    Oxford BioDynamics

    EpiSwitch technology

    EpiSwitch™ is a proprietary industrial platform for the discovery, evaluation, validation and monitoring of a novel class of epigenetic biomarkers known as ‘chromosome conformation signatures’ (“CCSs”). CCSs can provide a compelling, stable framework from which changes in the regulation of a

    Oxford BioDynamics

    What is ALS?

    ALS, also known as Motor Neuron Disease (MND), Lou Gehrig’s Disease, and Charcot’s disease, is a progressive neurodegenerative disease which attacks motor neurons in the brain and spinal cord resulting in the wasting away of muscle

    Oxford BioDynamics

    Oxford Biodynamics publish Annual Report

    Oxford BioDynamics (LON:OBD), a biotechnology company focused on the discovery and development of biomarkers based on regulatory 3D genome architecture, for use within the pharmaceutical and biotechnology industry, today announced that copies of its annual report

    Oxford BioDynamics

    What is EpiSwitchTM and how is it used?

    Grounded in Epigenetics Oxford BioDynamics’ EpiSwitch technology is based on epigenetics: mechanisms that alter gene expression without altering the underlying DNA sequence and whose deregulation plays a role in the development of cancer, autoimmune diseases, neurologic

    Oxford BioDynamics

    What is ALS?

    Amyotrophic Lateral Sclerosis (ALS) is a progressive neurological disease that destroys nerve cells in the brain  and the spinal cord and causes disability. It is also known as Lou Gehrig’s disease. The term “A-myo-trophic” is derived from the